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Abstract: 
Background: Little is known on the risk of cancer in HIV-positive children 
in sub-Saharan Africa. We examined incidence and risk factors of AIDS-
defining and other cancers in pediatric antiretroviral therapy (ART) 
programs in South Africa. 
 
Methods: We linked the records of five ART programs in Johannesburg and 
Cape Town to those of pediatric oncology units, based on name and 
surname, date of birth, folder and civil identification numbers. We calculated 
incidence rates and obtained hazard ratios (HR) with 95% confidence 
intervals (CI) from Cox regression models including ART, sex, age, and 
degree of immunodeficiency.  Missing CD4 counts and CD4% were 
multiply imputed. Immunodeficiency was defined according to World 
Health Organization 2005 criteria. 
 
Results: Data of 11,707 HIV-positive children were included in the analysis. 
During 29,348 person-years of follow-up 24 cancers were diagnosed, for an 
incidence rate of 82 per 100,000 person-years (95% CI 55-122). The most 
frequent cancers were Kaposi Sarcoma (34 per 100,000 person-years) and 
Non Hodgkin Lymphoma (31 per 100,000 person-years). The incidence of 
non AIDS-defining malignancies was 17 per 100,000. The risk of 
developing cancer was lower on ART (HR 0.29, 95%CI 0.09–0.86), and 
increased with age at enrolment (>10 versus <3 years: HR 7.3, 95% CI 2.2-
24.6) and immunodeficiency at enrolment (advanced/severe versus no/mild: 
HR 3.5, 95%CI 1.1-12.0). The HR for the effect of ART from complete case 
analysis was similar but ceased to be statistically significant (p=0.078). 
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Conclusions: Early HIV diagnosis and linkage to care, with start of ART 
before advanced immunodeficiency develops, may substantially reduce the 
burden of cancer in HIV-positive children in South Africa and elsewhere. 
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 INTRODUCTION 
South Africa is one of the countries most heavily affected by the HIV 
epidemic. An estimated 6.3 million people were living with HIV in South 
Africa in 2013, including 360,000 children.1 HIV-positive children are at 
higher risk of developing cancer than children from the general population 2-
4
 or HIV-negative children.5-8 Studies from Europe and the United States of 
America (USA) have shown that the incidence of cancer has declined as 
combination antiretroviral therapy (ART) has become more widely 
available.3, 4, 9 Cohort studies of HIV-positive children are rare in the African 
region, and no study has so far assessed the impact of ART on the risk of 
developing cancer.10 Moreover, data collection is often restricted to AIDS-
defining cancers, i.e. Kaposi sarcoma (KS) and non-Hodgkin Lymphoma 
(NHL) in these cohorts.11 Even the data on AIDS-defining cancers may be 
incomplete, since cohorts are based in ART programs but cancers are treated 
in pediatric oncology units. Record linkages with cancer registries can 
overcome these limitations but to date only one record linkage study from 
the pre-ART era reported the incidence rate of cancer in HIV-positive 
children in an African setting.12 Lastly, it may be difficult to estimate 
incidence and risk factors with precision because the number of HIV-
positive children followed-up in any single cohort is typically small. 
We did a record linkage study that combined data from five HIV 
cohort studies that participate in the International epidemiologic Databases 
to Evaluate AIDS (IeDEA) with the records of the four referral pediatric 
oncology units in South Africa. We aimed to define the incidence rate, risk 
factors and the impact of ART on the development of AIDS-defining and 
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non AIDS-defining cancers in HIV-positive children who attended 
antiretroviral therapy (ART) programs in South Africa. 
 
MATERIALS AND METHODS 
Data sources 
IeDEA is a research consortium established in 2006 to inform the 
scale-up of ART through clinical and epidemiological research.11, 13-15 The 
four African regions of IeDEA have been described in detail elsewhere.11 In 
this study, we included five South African treatment programs that provide 
care for HIV-positive children: the Khayelitsha Township ART program, the 
Tygerberg Hospital program and the Red Cross War Memorial Children’s 
Hospital program in Cape Town; and the Harriet Shezi and Rahima Moosa 
programs in Johannesburg.16 All five programs follow the guidelines of the 
South African National Department of Health17,18 and have approval from 
their local ethics committee to provide data to IeDEA. Data are collected in 
the context of routine care at baseline and each follow-up visit, including 
socio-demographic data, the date of starting ART, type of treatment 
initiated, and CD4 measurements and HIV-1 plasma RNA levels.11 The 
clinical and laboratory data are converted into a standardized format, the 
HIV Cohorts Data Exchange Protocol (HICDEP) and transferred to the 
IeDEA coordinating centers at the Centre for Infectious Disease 
Epidemiology and Research (CIDER), University of Cape Town, South 
Africa and the Institute of Social and Preventive Medicine (ISPM), 
University of Bern, Switzerland. The median date of the last follow up was 
August 19th 2010 (interquartile range 8 July 2008 to 2 June 2011).  
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 Record linkage 
HIV cohort data were linked with the records of four academic 
pediatric oncology referral units:19 the Red Cross War Memorial Children’s 
Hospital and the Tygerberg Hospital in Cape Town; and the Chris Hani 
Baragwanath and Charlotte Maxeke hospitals in Johannesburg. We included 
all HIV-positive children, aged 16 years or younger at enrolment, followed 
up at one of the five ART programs, and all patients with a confirmed cancer 
diagnosis and documented HIV-positive followed up at one of the four 
oncology units. We linked records probabilistically using the record linkage 
software G-Link of Statistics Canada,20 based on folder numbers, South 
African civil identification numbers, date of birth, sex, name and surname, 
ethnicity, date of death, and date of cancer diagnoses. Based on probability 
weights, possible matches were identified and confirmed or rejected after 
review. For each definite match, we retrieved data on the cancer diagnosis, 
including type, histology, date of diagnosis, stage and location and 
treatment. This information was anonymized and then incorporated into the 
IeDEA database.  
Definitions 
We defined the CD4 cell measurement at enrolment as the 
measurement closest to the enrolment date, within a window of 180 days 
before and 30 days after enrolment. We defined the CD4 measurement at 
start of ART as the measurement closest to the start of ART date, within a 
window of 180 days before and 30 days after ART was started. The degree 
of immunodeficiency (none, mild, advanced, severe) was defined using the 
WHO 2005 surveillance definition for the African region.21  
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We defined ART as a regimen of at least three antiretroviral drugs 
from at least two drug classes, including nucleoside reverse transcriptase 
inhibitors, non-nucleoside reverse transcriptase inhibitors and protease 
inhibitors. The calendar year of enrolment was categorized as before 2005 or 
thereafter. Calendar year of starting ART was categorized as before 2005, 
2005 to 2009 and 2010 onwards to reflect the scale up of ART in 2005 and 
changes in the South African ART guidelines in 2010.17,18 Prevalent cases 
were defined as cancers diagnosed before or at enrolment into the cohort. 
Incident cases were defined as cancers diagnosed during follow-up. 
Statistical methods 
In children not on ART, we measured time from the date of enrolment 
to the earliest of the date of diagnosis, start of ART, last follow-up visit or 
death. In children on ART, we measured time from the start of ART to the 
earliest of the date of the cancer diagnosis, last follow-up visit, or death. In 
children who were ART naïve at enrolment and who started ART during 
follow-up, we split the follow-up time so that they contributed time both to 
the not-on-ART and the on-ART analysis. We took an intent-to-continue-
treatment approach and ignored changes to ART regimens, including 
interruptions and terminations. Incidence rates were calculated by dividing 
the number of children who developed cancer by the number of person-years 
at risk, with Poisson 95% confidence intervals (CI). We examined risk 
factors for incident cancer in Cox proportional hazard models stratified by 
cohort. Multivariable models were adjusted for time-updated ART, age at 
enrolment, sex, and degree of immunodeficiency (none, mild, advanced, 
severe) at enrolment. Missing CD4 counts and CD4% were multiply 
imputed using predictive mean matching and chained equations stratified by 
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gender and age. In sensitivity analyses we restricted the analysis to the 
complete data and excluded patients with missing data.  
Results are presented as medians with interquartile ranges (IQR), 
incidence rates per 100,000 person-years, Kaplan-Meier estimates of the 
cumulative incidence and crude and adjusted hazard ratios (HRs), with 95% 
CI. Stata version 13 (Stata Corporation, College Station, Texas, USA) was 
used for all statistical analyses.  
 
RESULTS 
The five ART cohorts included 12,448 eligible children (Table 1, 
Figure 1). Almost half of children (5,810, 47%) were from the Harriet Shezi 
ART program in Johannesburg. Most children (10,529, 85%) were enrolled 
in 2005 or later, at a time when ART was scaled up in South Africa. The 
majority of children (8,764, 70%) started ART at or after enrolment. CD4 
cell measurements at enrolment were available for 7,995 (64%) children. Of 
these children, 5,333 (67%) presented with advanced or severe 
immunodeficiency (Table 1). The median CD4 cell count at enrolment was 
493 cells/µL (IQR 216-922), the median CD4% was 15% (IQR 9%-23%). 
Among children with missing CD4 cell measurements, the imputed median 
CD4 cell count was 664 cells/µL (IQR 396-906) and the imputed median 
CD4% was 16% (IQR 13%-19%) at enrolment. 
We identified a total of 71 eligible children with cancer: 49 (69%) 
were identified in the records of the oncology departments, 11 children 
(15%) were recorded with cancer in the ART programs, and 11 children 
(15%) were recorded in both data sets. Forty-seven children presented with 
cancer before or at enrolment, for a prevalence of 0.38% (95% CI 0.28-
0.50), and 24 children developed cancer during follow-up. Children who 
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presented with cancer or developed cancer later on were older at enrolment 
than children free of cancer: the median age at enrolment was 6.6 years and 
5.0 years in children with prevalent and incident cancer, respectively, and 
2.5 years in children not developing cancer. Children who developed cancer 
during follow-up were more likely to have experienced advanced or severe 
immunodeficiency than children who did not develop cancer (Table 1).  
Table 2 shows the characteristics of patients with prevalent and 
incident cancer at the time of cancer diagnosis. Fifty-one percent of children 
presented with advanced or severe immunodeficiency at the time of cancer 
diagnosis; in 42% of children the CD4 measurements were missing. In 
children with available data the median CD4 cell count at diagnosis was 372 
cells/µL (IQR 171-762) in children with prevalent cancer, and 599 cells/µL 
(IQR 62-978) in children with incident cancer. Most cancers were AIDS-
defining, including 21 prevalent and 10 incident cases of KS, and 20 
prevalent and 9 incident cases of NHL. Non AIDS-defining cancers included 
acute leukemias, Hodgkin lymphoma, nephroblastoma and leiomyosarcoma. 
Ninety percent of all cancers (64/71) were associated with Epstein Barr 
Virus (EBV) or HHV-8 co-infections (Kaposi sarcoma, lymphoma and 
leiomyosarcoma).  
Cancer incidence and risk factors for developing cancer 
The analyses of incidence were based on 11,707 children, of whom 24 
developed cancer during 29348 person-years (Figure 1). The median 
observation time was 2.0 years (IQR 6 months-4.0 years). In the 24 children 
with incident cancer, the median time from enrolment into ART program to 
cancer diagnosis was 46 days (IQR 15-287). At the time of analysis, 6401 
children (55%) were alive and under follow-up, 805 (7%) had died, 3,976 
(34%) had been transferred to a different clinic, and 525 (4%) were lost to 
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follow-up. In children on ART, the cancer incidence rate was 50/100,000 
person-years (95% CI 29-89); in children not on ART, the rate was 
220/100,000 person-years (95% CI 125-387) (Table 3). The incidence of 
AIDS-defining cancers was 65/100,000, with an incidence rate of 
34/100,000 for KS, and 31/100,000 for NHL. The incidence of non AIDS-
defining cancers was 17/100,000 person-years. The rate of cancer typically 
associated with EBV infection (NHL, Hodgkin lymphoma, leiomyosarcoma) 
was 34/100,000 person-years.  
Table 4 presents the results from univariable and multivariable Cox 
models from the main analysis based on imputed CD4 data and the 
sensitivity analysis based on complete cases. The multivariable models were 
adjusted for immunodeficiency, age at enrolment, gender and time-updated 
ART use.  
In the main analysis the multivariable model showed that children on 
ART had a lower risk of developing cancer than children not on ART (HR 
0.29, 95% CI 0.09-0.86). Children with severe or advanced 
immunodeficiency at enrolment were more likely to develop cancer than 
children with mild or no immunodeficiency (HR 3.54, 95% CI 1.05-11.79). 
The risk of developing cancer increased with age at enrolment (HR children 
aged >10 years versus aged <3 years 7.33, 95% CI 2.19-24.57). The hazard 
ratios from the univariable model were similar but tended to have wider 
confidence intervals. The effect of ART on the risk of cancer was less 
pronounced and failed to reach statistical significance (HR 0.43, 95% CI 
0.15-1.22). The hazard ratios from the analyses based on complete cases 
were similar to the analysis using multiply imputed data but the effect of 
ART on the risk of developing cancer was not statistically significant in this 
model (HR 0.23, 95% CI 0.04-1.18, Table 4).  
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 DISCUSSION 
This study shows that HIV-positive children in South Africa were at 
high risk of developing cancer with an overall incidence rate of 82/100,000 
person-years. The majority of cancers were AIDS-defining with an 
incidence rate of 34/100,000 person-years for KS and 31/100,000 person-
years for NHL. There were few non AIDS-defining malignancies with an 
incidence rate of 17/100,000 person-years. Children on ART had a 
substantially lower risk of developing cancer than children not on ART in 
multivariable analyses based on imputing data (HR 0.29, 95% CI 0.09-0.86). 
In complete case analysis the effect of ART was similar but not statistically 
significant. In all analyses the risk of developing cancer increased with age 
at enrolment.  
This is the first study to describe the incidence rate of AIDS-defining 
and non AIDS-defining cancer and to estimate the impact of ART on the risk 
of developing cancer in HIV-positive children in South Africa. We used 
record linkage to identify both AIDS-defining and non AIDS-defining 
cancer cases, which are often not recorded, or only incompletely recorded in 
the data of HIV care and treatment programs. However, we may have 
missed cancer cases in children who were lost to follow-up or who sought 
treatment in other clinics. We identified only 24 incident cancer cases, and 
this limited our ability to conduct analyses stratified for different cancer 
types. Measurements of CD4 cell counts and percentages, HIV RNA loads, 
weight and height at enrolment into cohort were missing for a substantial 
proportion of patients. To overcome this limitation we used multiple 
imputation methods to impute missing CD4 cell measurements. This is a 
relatively young cohort (median age 2.5 years) most likely due to inclusion 
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of many secondary and tertiary care sites where younger children and infants 
tend to be started on treatment. Given that we showed a strong association 
between older age and incident malignancy, the burden of malignancy may 
be higher in cohorts of older children. Median time between enrolment and 
cancer diagnosis was short and we cannot exclude that some of the cancers 
classified as incident cancer were actually prevalent cancers which had not 
been diagnosed before enrolment.  
Our study showed a cancer incidence rate of 69/100,000 person-years 
in HIV-positive children in the ART era (2005 or later), which is 
substantially higher than the Globocan 2012 cancer incidence rates in 
children aged < 14 years in South Africa (5/100,000 person-years), Europe 
(13/100,000 person-years), and the US (16/100,000 person-years).22 Our 
incidence rates are lower than estimates from previous studies done in HIV-
positive children in Europe and the US, see Table 5.3, 4, 9 It is difficult to 
directly compare studies because of different study designs, settings and 
populations. The US AIDS cancer match study2, 4 only included children 
diagnosed with AIDS, while the Italian HIV Registry9, 23 and our study also 
included children with HIV that had not yet progressed to AIDS. The Italian 
HIV Registry study was predominantly based on children aged under one 
year 9 whereas the median age at enrolment was 2.5 years in our study and 
6.3 years for the Pediatric AIDS Clinical Trials Group (PACTG) study.3 The 
PACTG study relied on reporting of cancer within the cohort3 whereas our 
and other studies included additional cases identified through record linkage 
with cancer registries.2, 4 The definition of incident, as opposed to prevalent 
cancer case also differed across studies. The US AIDS cancer match study 
considered incident cancer cases to be those diagnosed three months after 
AIDS onset,2, 4 but in our and other studies, any cancer recorded 
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immediately after enrolment into cohort or registry was classified as an 
incident cancer.3, 9, 23 More than 70% of all cancer cases identified in HIV-
positive children in Europe and the US were EBV-associated cancer (i.e. 
NHL and leiomyosarcoma) while HHV-8 associated KS accounted for less 
than 8%.3, 9 In contrast, in this South African study 46% of cancers were 
cancers that are typically associated with EBV, while 44% of all cancers 
were KS, which is typically associated with HHV-8. 
Despite these differences several of our results are in line with the 
findings of the previous studies. Children who received ART were at 
substantially lower risk of developing cancer than children not on ART. This 
finding is consistent with the results of studies from high income countries,3, 
4, 9
 see Table 5. Also, the risk of developing cancer tended to increase if 
immunodeficiency was more advanced at the time the child was enrolled 
into the cohort. This is in line with previous studies that showed that 
advanced stage HIV/AIDS disease,3, 9 or CD4 cell percentages below 15% 
(severely immunosuppressed), increased the risk of developing cancer.3  
Many cancer cases reported in our study were prevalent and detected 
at the time of enrolment into the program. Children with prevalent cancer 
presented late to the ART programs, at older ages and with severe or 
advanced immunodeficiency. Many of the prevalent cancers might have 
been prevented if the child had been enrolled into an ART program earlier. 
Indeed, early detection of HIV-infection, linkage to care and ART treatment 
may be crucial for preventing development of cancer in HIV-positive 
children in South Africa.24-28 Since 2013 the South African and WHO 
guidelines recommend starting ART in all HIV-positive children aged <5 
years regardless of immune status and at CD4 cell counts <350 cells/µL29 
and 500 cells/µL,30 respectively, in children aged >5 years. This 
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recommendation should contribute to further reduce the risk of developing 
cancer in HIV-positive children. The reasons why children present late to 
ART programs need to be elucidated and uptake of ART increased. To better 
understand how best to prevent cancer in HIV-positive children in African 
settings we also need to investigate the impact of different first and second 
line ART regimens, and of different monitoring strategies (i.e. CD4 
monitoring versus HIV viral load monitoring) on the risk of developing 
cancer. 
In conclusion, our study linking data from HIV treatment and care 
programs with oncology clinic data suggests that early HIV diagnosis, 
linkage to care and start of ART before advanced immunodeficiency 
develops may substantially reduce the burden of cancer in HIV-positive 
children.  
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 Legend to figure 1: 
The flow diagram shows the number of included and excluded patients. 
ART, antiretroviral therapy; IeDEA, International epidemiologic Databases 
to Evaluate AIDS 
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Table 1: Characteristics of HIV-positive children with prevalent and incident cancer in South Africa. 
  
Children with cancer  Children free from 
cancer 
  
Prevalent 
cases 
Incident cases  
All patients  47 24 12,377 
Cohort Harriet Shezi 18 (38%) 7 (32%) 5,785 (46%) 
 Khayelitsha 2 (4%) 1 (4%) 1,096 (9%) 
 
Rahima 
Moosa 1 (2%) 3 (16%) 2,752 (23%) 
 Red Cross 20 (42%) 6 (24%) 1,664 (13%) 
 Tygerberg 6 (15%) 7 (24%) 1,080 (9%) 
Gender Male 36 (77%) 14 (52%) 6,224 (50%) 
 Female 11 (23%) 10 (48%) 6,153 (50%) 
Age at enrolment Median 6.6 (4.3 – 5.0 (2.5 – 9.0) 2.5 (0.7 – 6.3) 
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[years] (IQR) 9.9) 
Age at enrolment ≤ 1 year 1 (2%) 2 (8%) 3,879 (31%) 
 
1 to < 3 
years 3 (6%) 5 (21%) 2,857 (23%) 
 
3 to < 5 
years 12 (26%) 5 (21%) 1,574 (13%) 
 
5 to < 10 
years 20 (43%) 7 (30%) 2,897 (23%) 
 ≥ 10 years 11 (23%) 5 (21%) 1,170 (10%) 
No / mild 6 (13%) 2 (8%) 2,654 (21%) 
Advanced / 
severe 
9 (20%) 9 (38%) 5,315 (43%) 
Immunodeficienc
y at enrolment* 
Missing 32 (68%) 13 (54%) 4,408 (36%) 
Before 
enrolment 19 (40%) 2 (8%) 1,924 (16%) 
Starting ART  
At or after 
enrolment 
27 (57%) 20 (83%) 8,717 (70%) 
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 cohort 
enrolment 
 
Never 
starting 
ART 
1 (2%) 2 (8%) 1,713 (14%) 
 Missing 0 0 23 (0.2%) 
Before 2005 11 (23%) 9 (38%) 1,213 (10%) 
≥ 2005 to 
2009 31(66%) 12 (50%) 7,628 (62%) 
≥ 2010 4 (9%) 1 (4%) 1,800 (15%) 
Calendar year of 
starting ART 
Never 
starting 1 (2%) 2 (8%) 1,713 (14%) 
 Missing 0 0 23 (0.2%) 
Before 2005 10 (21%) 10 (42%) 1,899 (15%) Calendar year of 
enrolment 
≥ 2005 37 (79%) 14 (58%) 10,478 (85%) 
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ART, antiretroviral therapy 
*WHO 2005 surveillance definition of immunodeficiency for the African region:21 No significant 
immunosuppression: children up to age 12 months >35 CD4%; children 13 – 59 months >25 CD4%; children ≥ 5 
years CD4 cell count > 500/mm3; Mild immunosuppression: children up to age 12 months 25-34 CD4%; children 
13 – 59 months 20-24 CD4%; children ≥ 5 years CD4 cell count 350-499/mm3; Advanced immunosuppression: 
children up to age 12 months 20-24 CD4%; children 13 – 59 months 15-19 CD4%; children ≥ 5 years CD4 cell 
count 200-349/mm3; Severe immunosuppression: children up to age 12 months <20 CD4%; children 13 – 59 
months < 15 CD4%; children ≥ 5 years CD4 cell count < 200/mm3.  
Table 2: Characteristics at the time of cancer diagnosis of HIV-positive children with prevalent and incident 
cancer in South Africa. 
  Children diagnosed with cancer 
  Prevalent cases Incident cases 
All patients  47 24 
Age at cancer Median (IQR) 6.0 (3.7 – 9.7) 6.3 (3.8 – 10.2) 
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diagnosis [years] 
Age at cancer 
diagnosis ≤ 1 year 1 (2%) 1 (4%) 
 1 to <3 years 6 (13%) 3 (13%) 
 3 to <5 years 12 (26%) 3 (13%) 
 5 to <10 years 18 (38%) 11 (46%) 
 ≥ 10 years 10 (21%) 6 (25%) 
CD4 cell count at 
cancer diagnosis* Median, IQR 372 (171 – 762) 599 (62 – 978) 
No / mild 3 (6%) 2 (8%) Immunodeficiency at 
cancer diagnosis** Advanced / severe 24 (51%) 12 (50%) 
 Missing 20 (43%) 10 (42%) 
ART history Not on ART 43 (91%) 12 (50%) 
 On ART 4 (8%) 12 (50%) 
Type of cancer HHV-8 associated, KS 21 (45%) 10 (42%) 
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 EBV associated 23 (49%)  10 (42%) 
   NHL, Burkitt   9 (19%)   3 (13%) 
   NHL, non Burkitt   10 (21%)   6 (25%) 
 
  NHL, CNS 
lymphoma   1 (2%)   0 
 
  Hodgkin 
lymphoma   3 (6%)   0 
   Leiomyosarcoma  0   1 (4%) 
 ALL, AML 0 4 (17%) 
 Other*** 3 (6%) 0 (0%) 
    
 
ART, antiretroviral therapy; HHV-8, human herpes virus 8; EBV, Epstein-Barr virus; NHL, non Hodgkin 
lymphoma; ALL, acute lymphocytic leukaemia; AML, acute myeloid leukaemia 
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*Based on 27 children with prevalent cancer and available CD4 count at cancer diagnosis, and 14 children with 
incident cancer and available CD4 count at cancer diagnosis.  
**WHO 2005 surveillance definition of immunodeficiency for the African region:21 No significant 
immunosuppression: children up to age 12 months >35 CD4%; children 13 – 59 months >25 CD4%; children ≥ 5 
years CD4 cell count > 500/mm3; Mild immunosuppression: children up to age 12 months 25-34 CD4%; children 
13 – 59 months 20-24 CD4%; children ≥ 5 years CD4 cell count 350-499/mm3; Advanced immunosuppression: 
children up to age 12 months 20-24 CD4%; children 13 – 59 months 15-19 CD4%; children ≥ 5 years CD4 cell 
count 200-349/mm3; Severe immunosuppression: children up to age 12 months <20 CD4%; children 13 – 59 
months < 15 CD4%; children ≥ 5 years CD4 cell count < 200/mm3. 
***Other: nephroblastoma, for two cases histology not provided 
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 Table 3: Incidence rates of cancer per 100,000 person-years in HIV-positive children in South Africa. 
 
  Person-years at 
risk 
No. of cancer 
cases 
Incidence 
rate  
(95% CI) 
Any cancer  29,348 24 82 (55 – 122) 
AIDS defining cancer     
   Any  29,360 19 65 (41 – 102) 
   KS  29,373 10 34 (18 – 63) 
   NHL  29,393 9 31 (16 – 59) 
Non AIDS defining 
cancer 
 29,393 5 17 (7 – 41) 
Gender     
Male  14,919 14 94 (56 – 158) 
Female  14,425 10 70 (37 – 129) 
Age at enrolment      
≤ 1 year  6,343 2 32 (8 – 126) 
1 to <3 years  7,362 5 68 (28 – 163) 
3 to <5 years  4,908 5 102 (42 – 245) 
5 to <10 years  8,197 7 85 (41 – 179) 
≥ 10 years  2,534 5 197 (82 – 474) 
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Immunodeficiency 
at enrolment     
No / mild  6,282 2 32 (8 –127) 
Advanced / severe  12,395 9 73 (38 – 140) 
Missing  10,666 13 122 (71 -210) 
ART treatment (time 
updated)     
Not on ART 
 5,464 12 220 (125 – 387) 
On ART  23,864 12 50 (29 – 89) 
Missing, unclear  16 0 - 
Calendar year of starting 
ART     
Before 2005  5,197 9 173 (90 – 333) 
≥ 2005 to 2009  20,627 12 58 (33 – 102) 
≥ 2010  1,822 1 55 (8 – 390) 
Missing / never starting  1,697 2 118 (30 – 471) 
Calendar year of 
enrolment     
< 2005  9,012 10 111 (60 – 206) 
≥ 2005  20,331 14 69 (41 – 116) 
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 ART, antiretroviral therapy; KS, Kaposi Sarcoma; CI, confidence interval.  
Copyright © 2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.AC
CE
PT
ED
 Table 4: Hazard ratios of developing cancer among HIV-positive children in South Africa 
 
 
Analysis based on imputed data 
(n=11,689) 
 Complete case analysis 
(n=7,646) 
   Univariable  Multivariable*  Univariable  Multivariable* 
Not on ART 1 1  1 1 ART treatment 
(time updated) On ART 0.43 (0.15-1.22) 0.29 (0.09-0.86)  0.23 (0.04-1.20) 0.23 (0.04-1.18) 
Male 1 1  1 1 Gender 
  
Female 0.74 (0.33-1.67) 0.69 (0.30-1.56)  0.88 (0.27-2.89) 0.86 (0.26-2.85) 
< 3 years 1 1  1 1 
3 to < 5 years 3.69 (1.15 – 11.84) 
3.41 (1.06 – 
10.97)  
7.77 (1.27 – 
47.34) 6.60 (1.08 – 40.44) 
5 to < 10 years 2.75 (0.95 – 7.97) 
2.89 (1.00 – 
8.36)  
5.67 (1.01 – 
31.81) 5.76 (1.02 – 32.46) 
Age at enrolment 
into ART program  
[years] 
≥ 10 years 7.05 (2.11 – 23.53) 
7.33 (2.19 – 
24.57)  
8.41 (1.11 – 
63.42) 8.29 (1.10 – 62.41) 
No / mild 1 1  1 1 Immunodeficiency 
at enrolment Advanced / 
severe 
2.59 (0.89 – 
7.57) 
3.54 (1.05 – 
11.97)  1.87 (0.40 – 8.72) 2.22 (0.45 – 10.87) 
Calendar year of  Before 2005 1 -  1 - 
starting ART ≥ 2005 to 2009 0.45 (0.17 – 1.17) -  0.45 (0.17 – 1.17) - 
 ≥ 2010 0.26 (0.03 – 2.27) -  0.26 (0.03 – 2.27) - 
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Calendar year of  Before 2005 1 -  1 - 
enrolment ≥ 2005 0.55 (0.22 – 1.35) -  0.58 (0.15 – 2.84) - 
 
ART, antiretroviral therapy; CI, confidence interval. 
All models were stratified by cohort. 
*Adjusted for time-updated ART, gender, age at enrolment and immunodeficiency at enrolment.  
Definition of immunodeficiency at enrolment into cohort according to WHO 2005 surveillance definition.  
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 Table 5: Literature review: cancer incidence in HIV-positive children in low, middle and high income 
countries 
 
Study Count
ry  
Childr
en 
include
d 
Cancer cases 
identified 
Cancer incidence rate per 100,000 pys (95% 
CI) 
% 
reducti
on 
    before ART era during ART era  
British Paediatric 
Association 
Surveillance Unit31 
UK 
 
307 11 (7 NHL) 1989-1995 
NHL: 1,420 
NA NA 
AIDS Cancer 
Match Study2 
USA 
 
4,954  124* (36 
incident in post 
AIDS period 4 
– 27 months) 
1980-1995: 656 NA NA 
AIDS Cancer 
Match Study4 
USA 
 
5,850  106* 1980-1995: 550 
    
 
 
1996-2007: 213 
    
 
 
 
61% 
 
Pediatric AIDS 
Clinical Trials 
Group PACTG3 
USA 2,969  37 (17 
prevalent, 20 
incident)** 
1993-1997: 201 (0–
414) 
 
1998-2003: 139 (74–
238) 
31% 
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Italian Register 
HIV Infection in 
Children23 
Italy 1,331  36 1985-1999: 418 (292–
302) 
 NA 
Italian Register 
HIV Infection in 
Children9 
Italy 1,190  35 1985-1995: 449 (237–
664) 
 
1996-1999: 409 (168–
650) 
2000-2004: 76 (0–180) 
 
83% 
 
Uganda Cancer 
Match Study12 
Ugand
a 
407 7, prevalent* 5, 
incident 2 (KS) 
1989-2002: 160  NA 
IeDEA-SA South 
Africa 
11,707 Total 71, 
prevalent 47, 
incident 24** 
2000-2004: 111 (60–
206) 
 
2005-2011: 69 (41–11) 38% 
 
 
ADC AIDS-defining cancer; NADC non AIDS-defining cancer; KS Kaposi Sarcoma; NHL non Hodgkin 
Lymphoma; IeDEA-SA International Epidemiological Databases to Evaluate AIDS in Southern Africa; pys person 
years; NA not available. *prevalent defined as: before or up to 3 months after AIDS, incident: later than 3 months 
after AIDS; **prevalent defined as: before cohort enrolment, incident: after cohort enrolment 
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